Understanding primary aldosteronism in patients from Western Norway
Primary Aldosteronism: a Study of Diagnostic Approach and Treatment Outcome in Western Norway
Haukeland University Hospital · NCT02832388
This study is looking to learn more about patients with primary aldosteronism in Western Norway by checking their heart health before and after treatment and comparing it to healthy individuals.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | Haukeland University Hospital (other) |
| Locations | 2 sites (Bergen and 1 other locations) |
| Trial ID | NCT02832388 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify and include patients diagnosed with primary aldosteronism (PA) in Western and Mid-Norway. It focuses on describing patient characteristics, exploring cardiac effects of PA before and after treatment, and assessing long-term outcomes. Subgroups of patients will undergo echocardiography and cardiac MRI to evaluate myocardial function and structure, with comparisons made to healthy controls. The study also aims to create a national registry of PA patients diagnosed or subtyped with adrenal vein sampling at Oslo University Hospital starting in 2025.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-85 with a verified diagnosis or strong suspicion of primary aldosteronism.
Not a fit: Patients with active cancer or certain respiratory conditions, as well as those who experience claustrophobia, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of primary aldosteronism, potentially enhancing patient outcomes.
How similar studies have performed: While the approach of assessing cardiac effects in PA patients is not widely tested, similar studies have shown promise in understanding the cardiovascular implications of hormonal disorders.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Verified diagnosis or strong suspicion of primary aldosteronism * Age 18-85 Exclusion Criteria: * Active cancer disease at time of inclusion Exclusion criteria for subgroup of primary aldosteronism-patients and healthy controls who perform cardiac MRI: * Asthma/chronic obstructive pulmonary disease , * Use of dipyridamole * Claustrophobia
Where this trial is running
Bergen and 1 other locations
- Haukeland University Hospital — Bergen, Norway (RECRUITING)
- Oslo University Hospital — Oslo, Norway (NOT_YET_RECRUITING)
Study contacts
- Principal investigator: Marianne A Grytaas, MD PhD — Haukeland University Hospital
- Study coordinator: Marianne A Grytaas, MD PhD
- Email: marianne.grytaas@helse-bergen.no
- Phone: +4741545435
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Hyperaldosteronism